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Abstract
Background: Gout and hyperuricaemia may be associated with increased cardiovascular risk, but analyses in
different populations show conflicting results. This study investigates the impact of serum uric acid, inflammation
and traditional CV risk parameters on CV event risk in patients with gouty arthritis and patients with non-gouty
rheumatic disease.
Methods: cross-sectional and prospective multivariate analysis of the relation between tertiles of serum uric acid
and individual traditional CV risk factors in a cohort of gouty arthritis (GA, n=172), rheumatoid arthritis (RA, n=480)
and osteoarthritis (OA, n=206) patients. Main outcome measures: systolic blood pressure, TC/HDL ratio, GlyHb, BMI
and first CV events.
Results: Individual CV risk factors were significantly less favourable in GA (systolic blood pressure, TC/HDL ratio, BMI,
p<0.05). In RA and OA, but not in GA, individual cardiometabolic parameters correlated with serum uric acid values
(OA: RA: systolic blood pressure, TC/HDL ratio, BMI; systolic blood pressure, TC/HDL ratio, GlyHb, BMI; p<0.05). In
non-GA individuals the highest tertile of serum uric acid (>0.34 mmol/L) and NT proBNP level were independent
predictors of first CV events, against age and GlyHb level in GA (p<0.05). The hazard of first CV events was equally
significantly increased in GA patients (HR 3.169, 95% CI 1.287-7.806) and non-GA individuals with a serum uric acid ≥
0.34 mmol/L (HR 3.721, 95% CI 1.603-8.634) compared to non-GA individuals with a serum uric acid < 0.27.
Conclusions: GA is associated with a 3.1-fold hazard of first CV events. In non-GA rheumatic patients increasing serum
uric acid is associated with increased CV risk, whereas CV risk in GA is independent of serum uric acid values. The
presence of GA or a baseline serum uric acid in the upper range are possibly stronger predictors of first CV events than
some traditional CV risk factors or parameters of inflammation.
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Background
Gouty arthritis (GA) was historically regarded “the king of
diseases and the disease of kings”. In modern times GA
has become the most prevalent form of inflammatory
arthritis and now it is primarily considered a complication
of unhealthy Western lifestyles [1,2]. Approximately 5 in
every 1000 individuals In European and North American
populations suffer from gouty attacks. These individuals
also have increased risk for other lifestyle diseases, most
notably cardiovascular (CV) events [3].
Gouty inflammation is caused by crystallisation and de-
position of uric acid in joints and surrounding tissues.
Thus, authors evaluating CV disease in gout have focussed
both on hyperuricaemia in a variety of patient populations,
and on gouty arthritis (GA) as a clinical entity. These stud-
ies show conflicting results. Often hyperuricaemia is found
to be an independent risk factor for CV events and death,
but in other studies these associations are lost after cor-
recting for traditional CV risk factors. Some studies only
find an association with the disease GA [4-17]. There are
different pathophysiologic hypotheses that may explain
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the observed associations: shared risk factors, direct meta-
bolic actions of uric acid on the vascular wall and/or on
renin-angiotensin-aldosterone and insulin resistance path-
ways, or vascular involvement in systemic inflammatory
activation. Even though all of these hypotheses are sup-
ported by experimental and/or epidemiologic data, none
has been definitely confirmed [18,19]. Causality in gout as-
sociated cardiovascular risk thus remains unelucidated
and pathways are probably complex.
Studies that evaluate the associations between serum
uric acid, inflammation and CV risk in rheumatic disease
are scarce [20,21]. We therefore investigated the associa-
tions between serum uric acid and CV risk parameters
and first CV events in patients with different rheumatic
diseases. To explore the value of serum uric acid level as a
marker of future CV event risk in rheumatic patients a
prospective multivariate analysis in GA and non-GA indi-
viduals was performed.
Methods
Data for this study were obtained from the Arthritis Cen-
ter Twente CardioVascular Disease (ACT-CVD) database.
In 2009 the Arthritis Center Twente in Enschede, the
Netherlands, established a per protocol cardiovascular
screening as standard care, which details have been de-
scribed previously [22]. Both existing and new patients are
screened for traditional CV risk factors and followed for
the occurrence of CV events. Briefly, the ACT-CVD data-
base is a collection of the routine clinical care parameters
obtained at the initial screening (demographics, traditional
CV risk factors, inflammatory parameters, rheumatic dis-
ease characteristics and medication), as well as CV event
follow up data for each patient. Patients are classified ac-
cording to their clinical diagnosis as registered by their
attending rheumatologist. After screening, each patient
is followed for the occurrence of CV events or death. CV
events are defined as (1) myocardial infarction; (2) coronary
intervention, i.e. percutaneous transluminal coronary angio-
plasty (PTCA) or coronary artery bypass graft (CABG); (3)
angina pectoris, confirmed by a cardiologist as cardiac chest
pain; (4) acute heart failure; (5) cerebral vascular accident
(CVA); (6) death due to cardiac causes; (7) sudden death.
Follow up data are extracted from the hospital electronic
registration system and subsequently validated by medical
chart review. Out of hospital events and death are docu-
mented by periodic questionnaires sent to attending general
practitioners and by review of the Dutch national registry
of death certificates. For this study the data of all patients
without prior documented CV event and with a diagnosis
of either rheumatoid arthritis (RA), osteoarthritis (OA) or
gouty arthritis (GA) that were screened between February
2009 and December 2011 were selected. Patient follow up
ended at December 2012.
In the analysis we used the following definitions: hyper-
uricaemia: serum uric acid above 0.36 mmol/l in women
or 0.40 mmol/l in men; uric acid lowering therapy (ULT):
two or more consecutive prescriptions of allopurinol and/
or benzbromarone covering at least a 3 months interval;
antihypertensive therapy: the use of beta-blocking agents,
calcium antagonists, angiotensin converting enzyme inhibi-
tors, angiotensin receptor inhibitors and/or diuretic regis-
tered for use as an antihypertensive agent; smoking: the
current use of inhaled tobacco; diabetes: the use of glucose
lowering medication and/or a fasting plasma glucose above
6.9 mmol/l. Glomerular filtration rate (GFR) as a param-
eter of renal function was estimated using the ‘modification
of diet in renal disease’ (MDRD) formula [23]. Body mass
index (BMI) was calculated as the ratio between weight
and the square of length.
To evaluate patterns in associations between uric acid
and CV risk parameters among rheumatic patients and
to define homogeneous groups for the prospective analysis
a first cross sectional analysis was performed of the rela-
tion between tertiles of serum uric acid and the baseline
traditional CV risk parameters systolic blood pressure,
total cholesterol/high density lipoprotein (TC/HDL) ratio,
glycated haemoglobin (GlyHb) and BMI in patients with
individual rheumatic diagnoses. In the prospective COX-
regression analysis the predictive value of uric acid tertiles
for the occurrence of first CV events in the ACT-CVD
population was evaluated considering all abovementioned
traditional CV risk parameters and the variables age, sex,
high sensitivity CRP (hsCRP), N-terminal pro-brain natri-
uretic peptide (NT-proBNP), estimated GFR, use of anti-
hypertensive therapy or statins, and in GA patients use of
allopurinol or ULT in general. For the prospective analysis
duration of follow up was calculated as the interval be-
tween inclusion into the cohort and the occurrence of a
first CV event or death, or censored at December 1st
2012, whichever came first.
The protocol for data collection, storage, and use in the
present study was approved by the Arthritis Center Twente
Institutional Review Board. Because the study uses data col-
lected as part of daily clinical care the ethics committees
determined, in accordance to Dutch law, that no approval
was required. Nonetheless, patients were fully informed
and only the data of patients that gave informed consent
were entered into the ACT-CVD database.
Statistical analysis
Prevalence of CV risk factors in patient groups and 10-year
CV risk estimates were presented by descriptive statis-
tics (mean or percentage prevalence). Differences be-
tween groups and associations between CV risk variables
and tertiles of serum uric acid were tested with ANOVA
(for continuous CV risk factors) or Chi squared statistics
(for nominal CV risk factors), adjusted for differences by
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age and sex. For the survival analysis those groups that
showed similar baseline patterns of CV risk parameters in
tertiles of serum uric acid and equal occurrence of first
CV events were combined. Kaplan Meier curves were
made for CV event free survival over time and backwards
stepwise COX regression analysis was performed to deter-
mine the value of tertiles of uric acid as an independent
predictor for CV event risk over time. Data analysis was
performed using PASW Statistics version 18.0.
Results
After the first year of screening the completed data of 973
individuals with GA (n = 204), RA (n = 533), or OA (222)
were available for analysis. Of these individuals 133 (32
GA, 38 RA, 14 OA) were excluded because of prior CV
events. Prior CV events were significantly more frequent
in GA patients (p < 0.05).
Baseline CV risk
The baseline characteristics of the study population are
presented in Table 1. Distributions of age and sex were
as expected. Individuals were predominantly late middle
aged, with overrepresentation of women in RA and OA,
and men in GA. The hsCRP level, a measure of systemic
inflammation, was significantly lower in OA.
At baseline the distributions of the traditional CV risk
parameters male sex, systolic blood pressure, TC/HDL ra-
tio, and BMI were significantly less favourable in GA pa-
tients (p < 0.05). In RA and OA the individual CV risk
parameters systolic blood pressure, TC/HDL ratio and
BMI, and in OA also GlyHb, all correlated with serum uric
acid levels (Figure 1). In GA no associations between serum
uric acid and individual CV risk parameters were observed.
The majority of gout patients (73%) used ULT (88% allo-
purinol, 12% benzbromarone). Mean serum uric acid was
significantly lower in patients using ULT (0.32 mmol/l ULT
vs. 0.48 mmol/l Non-ULT, p < 0.05). Patients treated with
allopurinol had significantly lower hsCRP (14.1 ± 22.6 vs.
4.40 ± 4.41 g/L) and NT-proBNP (76.7 ± 313.7 vs. 24.0 ±
70.2 pmol/L) levels than non-allopurinol treated patients.
Otherwise, these patients did not differ in baseline mea-
surements of traditional CV risk factors, or in frequency of
treatment with statin or antihypertensive therapy.
Prospective analysis of CV events
After a median follow up of 36 months (25th- 75th per-
centile 30–41) 64 CV events had occurred, 29 (6.0%)
Table 1 Baseline characteristics
GA (172) RA (480) OA (206)
Serum uric acid, mean, mmol/l (SD) 0.36 (0.14) 0.31 (0.075)** 0.31 (0.0832)**
Hyperuricaemia, n (%) 54 (32)† 62 (14)† 34 (17)†
Uric acid lowering therapy, n (%) 126 (73) 0 0
Allopurinol, n (%) 111 (65) 0 0
Sex, n (%) male 154 (89) 133 (28)** 43 (21)**
Age, mean, years (SD) 59.6 (10.8) 59.0 (13.0) 59.2 (11.0)
Systolic blood pressure, mean, mmHg (SD) 151.0 (21.3) 144.0 (22.9)** 145.5 (20.2)**
Antihypertensive therapy, n (%) 67 (39.0) 118 (24.6) 71 (34.5)
Smoking, n (%) 43 (25) 114 (24) 38 (18)
TC/HDL ratio, mean (SD) 4.82 (1.4)† 3.65 (1.1)† 4.0 (1.2)†
Total cholesterol, mean (SD) 5.32 (1.1) 5.30 (1.0) 5.57 (1.1)
HDL cholesterol, mean (SD) 1.17 (0.32) 1.53 (0.43) 1.48 (0.39)
Statin therapy, n (%) 22 (12.8) 32 (6.7)‡ 26 (12.6)
Diabetes, n (%) 11 (6.4) 28 (5.8) 16 (7.8)
GlyHb, mean, % Hb (SD) 6.1 (1.4) 5.5 (1.8) 6.0 (4.2)
BMI, mean, kg/m2 (SD) 30.4 (4.7)† 27.0 (4.3)† 28.8 (5.3)†
MDRD, mean, ml/min (SD) 80.8 (21.8) 89.9 (19.5)** 87.7 (18.7)**
NT proBNP, mean, nmol/L (SD) 37.6 (170.6) 15.9 (25.8)** 15.1 (32.8)**
hsCRP, mean, g/L (SD) 6.3 (11.2) 7.0 (10.0) 3.8 (4.9)*
Corticosteroids, n (%) 0 (0.0) 68 (14.2)¥ 1 (0.50)
GA: gouty arthritis; OA: osteoarthritis; RA: rheumatoid arthritis; hsCRP: high sensitivity C-reactive protein; SD: standard deviation; CV: cardiovascular; TC: Total
cholesterol; HDL: high density lipoprotein; GlyHb: glycated haemoglobin; BMI: body mass index; MDRD: modification of diet in renal disease; NT proBNP:
N-terminal pro-brain natriuretic peptide. *p < 0.05 OA vs. RA and GA, **p < 0.05 RA and OA vs. GA, †p < 0.05 RA vs. OA vs. GA, ‡p < 0.05 RA vs. OA and GA.,
¥p < 0.05 RA vs. GA and OA.
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RA, 17 (8.3%) OA, and 18 (10.5%) GA. Five of these first
CV events were fatal, 2/29 (6.9%) in the RA, 0/17 (0.0%)
in the OA group, and 3/18 (16.6%) in the GA group. Be-
cause baseline patterns of traditional CV risk factors in
tertiles of uric acid were similar and the occurrence of
CV events did not differ significantly between RA and
OA patients, the data of RA and OA groups were com-
bined as ‘non-GA’ for further survival analysis. Table 2
shows the univariate associations between baseline vari-
ables and occurrence of CV events in non-GA and GA
groups.
In female GA patients the frequency of CV events was
unexpectedly high: 5/18 (28%) vs. 13/154 (8.4%) in male
GA patients, 29/510 (5.7%) in female non-GA patients
and 17/176 (9.7%) in male non-GA patients. Female GA
patients were significantly older than male GA patients
(female GA mean 70 years ± 10.2 vs. male GA 58 years ±
10.2, p < 0.05), whereas female and male non-GA patients
were of comparable age (female non-GA mean 58 years ±
12.6 vs. male GA 58 years ± 12.0, p = 0.465).
For both GA and non-GA groups all variables with p ≤
0.150 were included in the backwards stepwise COX regres-
sion analyses. The use of uric acid lowering, antihyperten-
sive and/or statin therapy were considered as possible
confounders. In the non-GA group the highest tertile of
serum uric acid (≥0.34 mmol/L; HR 3.896, 95% CI 1.677-
9.051) and NT proBNP (HR 1.012, 95% CI 1.008-1.016)
level remained as independent predictors of CV events,
against age (HR 1.073, 95% CI 1.022-1.127) and GlyHb level
(HR 3.273, 95% CI 1.971-5.434) in the GA group (p <
0.05). Compared to non-GA individuals with a serum uric
acid < 0.27, non-GA individuals with a serum uric acid ≥
0.34 mmol/L (HR 3.721, 95% CI 1.603-8.634) and GA pa-
tients (HR 3.169, 95% CI 1.287-7.806) showed equally in-
creased hazard ratio’s for first CV events (Figure 2).
Discussion
Our data show that GA is associated with a more un-
favourable traditional CV risk profile and a 3.1-fold hazard
of first CV events compared to non-GA individuals with
normal serum uric acid. In non-GA individuals increasing
serum uric acid is associated with increased CV risk, the
3.7 fold hazard of a first CV event in non-GA individuals
with a serum uric acid ≥ 0.34 mmol/L being comparable
with that of gout patients.
Individual traditional CV risk factors, such as systolic
blood pressure, serum lipoproteins, and body mass index,
and occurrence of first CV events were increased at the
same level in subsequent tertiles of serum uric acid in
both RA and OA. These associations thus seem relatively
independent from chronic inflammation. Compared to the
other rheumatic populations mean serum uric acid values
were highest in GA, as were values of traditional CV risk
factors. First CV events were also more frequent in GA
*
*
†**
*
*
*
*
*
†
†
†
A
B
C
*
Figure 1 Associations between baseline cardiovascular risk
parameters (A-C) and tertiles serum uric acid in GA, RA and OA.
Tertiles serum uric acid (1st, 2nd, 3rd): GA: <0.29 mmol/L, 0.29-0.38
mmol/L, and ≥0.39 mmol/L; RA: <0.27 mmol/L, 0.27-0.34 mmol/L,
and ≥0.34 mmol/L; OA <0.27 mmol/L, 0.27-0.34 mmol/L,
and ≥0.34 mmol/L. GA: gouty arthritis; RA: rheumatoid arthritis;
OA: osteoarthritis; TC: total cholesterol; HDL: high density
lipoprotein; BMI: body mass index. (*p < 0.05 vs. 1st tertile;
‡p < 0.05 vs. 2nd tertile).
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individuals than in non-GA patients. The frequency of first
CV events was particularly high in female GA patients. This
may be explained by the age of female GA patients, which
was 10 years increased compared to the other patient
groups, increasing age beyond the menopause being an im-
portant CV risk factor in women. The relatively high age of
the female GA patients included in the ACT-CVD cohort
is in line with previously published epidemiologic studies
[24]. Another explanation could be selection bias due to
the small number of female GA patients included.
Individual CV risk parameters and prospective CV events
were not related to tertiles of serum uric acid in GA pa-
tients. This may be due to confounding by the use of uric
acid lowering therapy or more specifically the xantine oxi-
dase inhibitor allopurinol, or to a ceiling effect in the gener-
ally high risk GA patients. CV risk factor values were not
lower in GA patients treated with UTL or specifically allo-
purinol, and CV events were as frequent. The only sugges-
tion in our data that treatment with allopurinol may be
beneficial was the significantly lower mean level of NT
proBNP, a marker of cardiac dysfunction, in this group.
Comparison to the literature
Previously, several large studies found increased CV dis-
ease and mortality in patients with gout, approximately
two-fold compared to the general population [25-27]. To
determine if hyperuricaemia per se confers the same risk of
increased CV disease different populations have been stud-
ied; the general population, young and elderly, diabetics
and patients with chronic kidney disease [4,6-17,28-30].
Many studies did find hyperuricaemia to be an independent
risk factor, but in others the association disappeared after
correction for the traditional CV risk factors obesity, hyper-
tension, dislipidemia and/or insulin resistance. Some stud-
ies found a U- or J-shaped association between serum uric
acid level and mortality, suggesting an optimal level be-
tween 0.30 and 0.41 mmol/L [29-31]. Only one study spe-
cifically addressed the role of systemic inflammation in GA
related CV disease, and found no association with CV
events [7].
The question remains if serum uric is only a potentially
useful marker to improve the selection of high CV risk in-
dividuals for CV risk management, or if it is causally related
to the progression of CV disease. Different hypotheses have
been suggested: 1) the presence of shared risk factors in CV
disease and GA, 2) vascular wall activation and accelerated
atherosclerosis by chronic systemic inflammation, or 3) a
direct interaction of uric acid with diverse metabolic path-
ways involved in CV disease [18,19]. Several experimental
studies have provided insight into possible actions of uric
Table 2 Univariate associations between CV risk variables and prospective CV events in GA and non-GA patients
GA (172) Non-GA(686)
Event-free (154) Event (18) p (event vs. none) Event-free (640) Event (46) p (event vs. none)
Tertiles serum uric acid (% 1st/2nd/3rd) 37.3/32.0/30.7 33.3/16.7/50.0 0.208 40.6/28.3/31.2 15.9/25.0/59.1 0.000*
Uric acid lowering therapy, % 74.0 66.7 0.504 0 0 n.a.
Allopurinol, % 64.3 66.7 0.842 0 0 n.a.
Sex, % male 91.6 72.2 0.011* 24.8 37.0 0.069*
Age, mean, years 58.5 68.8 0.000* 58.6 64.9 0.001*
Systolic blood pressure, mean, mmHg 152.0 143.0 0.092* 143.9 152.1 0.015*
Antihypertensive therapy, % 34.4 77.8 0.000* 26.3 45.7 0.004*
Smoking, % 26.0 11.1 0.147* 22.0 23.9 0.767
TC/HDL ratio, mean 4.83 4.71 0.623 3.74 3.95 0.265
Total cholesterol, mean 5.38 4.83 0.037* 5.38 5.19 0.234
HDL cholesterol, mean 1.18 1.05 0.104* 1.53 1.40 0.057*
Statin therapy, % 11.7 22.2 0.205 8.0 15.2 0.088*
Diabetes, % 5.8 11.1 0.387 6.4 6.5 0.975
GlyHb, mean, %Hb 5.83 6.58 0.004* 5.83 5.91 0.408
BMI, mean, kg/m2 30.1 32.9 0.017* 27.4 28.8 0.058*
MDRD, mean, ml/min 83.5 58.1 0.002* 89.7 83.2 0.091*
NT proBNP, mean, nmol/L 14.5 230.9 0.083* 14.1 45.4 0.005*
hsCRP, mean, g/l 5.76 9.44 0.238 5.90 7.21 0.390
Corticosteroids, % 0.0 0.0 - 10.0 10.9 0.850
GA: gouty arthritis; hsCRP: high sensitivity C-reactive protein; TC: Total cholesterol; HDL: high density lipoprotein; GlyHb: glycated haemoglobin; BMI: body mass
index; MDRD: modification of diet in renal disease; NT proBNP: N-terminal pro-brain natriuretic peptide. *variable included in the respective COX
regression analyses.
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acid in diverse metabolic pathways, i.e. glucose and
lipoprotein handling, nitric oxide metabolism, the renin-
angiotensin-aldosterone system (RAAS), and inflamma-
tory signalling and activation [32-34]. These observations
suggest that uric acid itself can at least modulate CV risk
factors such as blood pressure, cholesterol, diabetes and
chronic inflammation [35]. Uric acid clearance may be de-
creased in states of hypertension and RAAS activation,
with consequent increasing hyperuricaemia and amplifica-
tion of metabolic derangements. However, other studies
suggest that the metabolic effects attributed to uric acid
are actually mediated by xantine oxidase, which is also the
key enzyme in uric acid production in man. Increased
serum uric acid may thus only be an epiphenomenon of
other pathologic metabolic pathways that cause increased
CV risk [36].
Strengths and limitations
Our study adds to the knowledge on hyperuricaemia and
CV risk by comparing the association between serum uric
acid and CV-risk in a mixed rheumatic population includ-
ing GA. Thus we saw that in this population either the
presence of GA or a baseline serum uric acid in the upper
range are stronger predictors of first CV events than some
traditional risk factors or parameters of inflammation. Epi-
demiologic studies that evaluate associations of serum uric
acid with traditional CV risk factors and prospective CV
events in a rheumatic population are scarce. In this study
the study groups were well defined and measurements of
risk factors were performed within the same protocol.
However, this study has some important limitations.
First, the observational study design precludes any sugges-
tions on causal relationships. Thus the absence of an asso-
ciation between serum uric acid and CV risk in GA was
difficult to interpret due to the pre-treated population. Be-
cause we only had data on baseline variables we could not
evaluate of the effect of medical interventions and changes
in serum uric acid on CV outcome. A possible risk reduc-
tion by allopurinol may not have followed from our data
due to insufficient numbers of patients, too short period
of exposure or too short follow up. Following the data one
can only conclude that also in a ULT treated GA popula-
tion with satisfactory mean uric acid levels CV risk is high.
The prospective analysis, evaluating the associations of a
limited set of traditional CV risk factors and serum uric
acid tertiles in a mixed population of articular diseases, is
a simplification that may ignore any disease specific CV
risk factors. Moreover, the rheumatic diseases studied dif-
fer importantly in general gender epidemiology, reflected
by a male predominance in the GA group versus a female
predominance in the non-GA group. Gender is an import-
ant traditional CV risk factor. Therefore, gender, diagnosis
Figure 2 Comparison of cardiovascular event-free survival in GA and non-GA patients. Comparison of cardiovascular event-free survival in
GA patients and in tertiles serum uric acid (<0.27 mmol/L, 0.27-0.34 mmol/L, and ≥0.34 mmol/L) in non-GA patients. GA: gouty arthritis.
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and hsCRP were considered as variables in the multivari-
ate analysis, but proved non-significant. The influence of
some other potential confounders such as use of NSAIDs
and relative physical inactivity was not covered by separate
variables, but regarded to be limited by only including pa-
tients with rheumatic diseases.
Some important questions remain for further research.
First, the predictive value of pre-ULT treatment uric acid
level for the occurrence of CV events in GA patients.
Second, the positioning of uric acid and xantine oxidase
in pathophysiologic pathways that cause CV events in
GA and hyperuricaemia. And finally, what is the optimal
risk intervention strategy in high CV risk patients char-
acterised by an upper range uric acid level.
Conclusions
Both gouty arthritis and, in non-gouty rheumatic patients,
upper range serum uric acid are associated with an ap-
proximately 3-fold hazard of first CV events. CV risk in
gouty arthritis is independent of serum uric acid values
and remains important in patients treated to satisfactory
uric acid values by uric acid lowering therapy. The pres-
ence of a diagnosis of gouty arthritis or a baseline serum
uric acid in the upper range are possibly stronger predic-
tors of first CV events than some traditional CV risk fac-
tors or parameters of inflammation.
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